ANKRD20A19P: A Potential Drug Target and Biomarker (G400110)

Target Name: ANKRD20A19P

NCBI ID: G400110

ANKRD20A19P

Other Name(s): Ankyrin repeat domain 20 family member A19, pseudogene | ankyrin repeat domain 20 family member A19, pseudogene

ANKRD20A19P: A Potential Drug Target and Biomarker

Introduction

Ankyrin repeat domains (ANKRDs) are a class of non-coding DNA sequences that have been identified in various organisms as having transcript regulatory functions. ANKRD20A19P is a member of the ANKRD family and has been identified as a potential drug target and biomarker. This article will introduce the basic information, functions, research status and future research directions of ANKRD20A19P.

Basic Information

ANKRD20A19P is a DNA sequence 20 nucleotides in length. It is located in the chromosome 19 region of the human genome and belongs to the long non-coding RNA (lncRNA) family. ANKRD20A19P starts from a protein-coding gene, and its downstream contains some known functional elements, such as miRNA binding site, RNA binding protein (RBP) binding site, and DNA-binding protein (DNA-binding protein) binding site. wait.

Function

The function of ANKRD20A19P is to regulate gene expression by binding to miRNA and RBP. MiRNAs are a class of non-coding RNA molecules, mainly encoded by genes, that inhibit translation by binding to the 5' end of target mRNA. miRNA plays an important role in regulating gene expression and is an important factor in the occurrence and development of many diseases. By binding to miRNA, ANKRD20A19P can inhibit the translation of target mRNA, thereby inhibiting the progression of the disease.

Studies have shown that the miRNA binding site of ANKRD20A19P can bind to miR-18a, a 20-22nt long miRNA molecule widely present in various organisms. By binding to miR-18a, ANKRD20A19P can regulate the expression of miRNA target mRNA. In addition, some studies have also shown that ANKRD20A19P can bind other types of miRNA molecules, such as miR-124, miR-18a, etc.

Research status

At present, research on ANKRD20A19P mainly focuses on its role in the regulation of gene expression. Many studies have explored the binding mode of ANKRD20A19P with miRNA and RBP and its role in signaling pathways. Some studies have also explored the application of ANKRD20A19P gene knockout technology in disease treatment.

future research directions

1. Interaction network of ANKRD20A19P: In-depth study of the interaction mode of ANKRD20A19P with miRNA and RBP to reveal its mechanism of action in the regulation of gene expression.

2. Clinical application of ANKRD20A19P: Explore the clinical application of ANKRD20A19P as a potential drug target or biomarker.

3. Gene knockout technology of ANKRD20A19P: Study the gene knockout technology of ANKRD20A19P and explore its application in disease treatment.

in conclusion

ANKRD20A19P is a functional non-coding RNA molecule that plays an important role in the regulation of gene expression. By binding to miRNA and RBP, ANKRD20A19P can regulate the expression of miRNA target mRNA, thereby inhibiting disease progression. In the future, researchers will continue to conduct in-depth studies on the interaction network, clinical applications and gene knockout technology of ANKRD20A19P, hoping to bring new ideas and progress to the treatment of the disease.

Protein Name: Ankyrin Repeat Domain 20 Family Member A19, Pseudogene

The "ANKRD20A19P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD20A19P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets